New adjuvants: EU regulatory developments (Q36968305)

17 August 2017

1 reference

title

New adjuvants: EU regulatory developments (English)

1 reference

17 August 2017

Dorothea Sesardic

1

1 reference

17 August 2017

Sjoerd Rijpkema

series ordinal

2

1 reference

17 August 2017

Brijesh Prakash Patel

series ordinal

3

1 reference

17 August 2017

publication date

1 October 2007

1 reference

Expert Review of Vaccines

17 August 2017

published in

1 reference

17 August 2017

volume

6

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

849-861

1 reference

Non-clinical safety evaluation of novel vaccines and adjuvants: new products, new strategies

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

European union regulatory developments for new vaccine adjuvants and delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Non-clinical vaccine safety assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Adjuvants for human vaccines--current status, problems and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

(How) do aluminium adjuvants work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Immunological concepts of vaccine adjuvant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

The development and use of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Survey of human-use adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Vaccine adjuvants: current state and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

New technology platforms in the development of vaccines for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Targeting the innate immune response with improved vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Vaccine adjuvants revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Recent advances in vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Using bicistronic IL-4 reporter mice to identify IL-4 expressing cells following immunisation with aluminium adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Vaccinology: past achievements, present roadblocks and future promises

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Inflexal V--the influenza vaccine with the lowest ovalbumin content

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

A hepatitis B vaccine formulated with a novel adjuvant system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Intussusception among infants given an oral rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Design and selection of vaccine adjuvants: animal models and human trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Mucosal antibody response induced with a nasal virosome-based influenza vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and immunogenicty of RTS,S/AS02A candidate malaria vaccine in Gambian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Humoral and cell-mediated immune responses of humans to inactivated influenza vaccine with or without QS21 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Immediate-type hypersensitivity and other clinical reactions in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.6.5.849

21 January 2018

Identifiers

DOI

10.1586/14760584.6.5.849

1 reference

17 August 2017

1 reference